As we finish up the week, we've identified some stocks that have had some strong moves to this upside in the past few days. Now let's hop into the details and show you what we found!
Genprex Inc (Nasdaq: GNPX) is one of the few clinical stage companies offering exciting investment opportunities in a segment growing at a compound annual growth rate of 19.1%.
It is one of the few plays trading at highly discounted levels while developing therapies and technologies for treating a range of disorders, such as inherited diseases and cancers. Rather than treating patients with drugs or surgeries, Genprex is working on therapies that insert genes into a cell to cure various diseases caused by genetic variants. Gene therapies stand out partly because they are one-time events, although there might be additional dosages.
With the Gene therapy market expected to grow to $29.47 billion from $7.54 billion in 2022, there is every reason to be bullish about Genprex's growth metrics and long-term prospects.
Here are a few reasons why Genprex should be on your watchlist.
TOP GNPX HIGHLIGHTS
* GNPX stock is trading near a 52-week low with RSI near 46 - A strong bounce can happen at anytime.
* Dawson James has a Buy rating on the stock and an average price target of $5.61 - representing over 500% upside potential from current levels.
* Genprex is home to some of the best technologies designed to administer disease-fighting genes most effectively.
* Genprex has made impressive strides in developing REQORSA, its novel treatment for lung cancer.
* With the Gene therapy market expected to grow to $29.47 billion from $7.54 billion in 2022, there is every reason to be bullish about Genprex's growth metrics and long-term prospects.
Robust Gene Therapy Technologies
Genprex (GNPX) is home to some of the best technologies designed to administer disease-fighting genes most effectively. As a result, its technologies have the potential to provide new breakthrough therapies for large patient populations struggling with cancer and diabetes.
Nanoparticle Delivery System is the first systemic gene therapy delivery platform that can be used to enclose plasmids that deliver tumor suppressor genes. It also administers encapsulated plasmids which are taken up by tumor cells and express any missing proteins in the tumor cells.
In addition, the company has REQORSA, a leading immunogen therapy drug for non-small cell lung cancer. The therapy is administered through the company's systemic gene therapy platform for cancer.
Finally, Genprex boasts of game-changing GPX-002, a diabetes gene therapy comprising a novel infusion process. It relies on an endoscope and adeno-associated virus vector to deliver Pdx1 and Mafia to the pancreas.
Lung Cancer Treatment
REQORSA is the company's lead candidate drug currently in clinical trials for the treatment of non-small cell lung cancer and small cell lung cancer. The novel treatment positions Genprex to be a key player in treating lung cancer, the leading cause of death worldwide. Lung cancer causes more deaths than colorectal, breast, liver and stomach cancer. With the limited benefit from current therapies, Genprex novel candidate drug has what it takes to address the unmet medical need, more so in lung cancer patients.
After successful clinical trials, the candidate drug has already received fast-track designation from the Food and Drug Administration. In a recent Acclaim-1 phase, ½ clinical trial REQORSA, combined with tagrisso(R) (osimertinib) for treating small cell lung cancer, was well tolerated with no dose-limiting toxicities. The Safety Review Committee has already approved continuation into phase 2 expansion. A combination of REQORSA and Osimertinib has already received Fast Track designation from the FDA for use in the Acclaim-1 patient population.
Genprex (GNPX) is already conducting preclinical research as it looks to explore REQORSA's potential use in other solid tumors. It is also exploring how other cancer-fighting genes can be used on its non-viral gene therapy platform.
Multidisciplinary Management Team
Genprex's (GNPX) long-term prospects are further affirmed by its multidisciplinary team of executives and advisors. The broad business experience in biotech and pharmaceutical that the team brings should allow the company to accelerate the development of its novel treatment for lung cancer and address the significant unmet medical need.
The management team boasts of highly experienced personnel as part of its scientific advisory board that reviews research and development activities and provides recommendations to accelerate the development of the moving treatment. There is also a clinical advisory board tasked with overseeing clinical trials to ensure they are up to board or approval by the FDA.
While insiders own about 4.5% of GNPX, their interests are perfectly aligned with that of investors. Likewise, institutions owning about 7.8% of the stock underscore the strong belief in the company's gene therapy pipeline.
In the near term, the investment community could elevate the value of GNPX closer to that of its peers.
GNPX has made about an 25% in the past two trading sessions and is testing a key level for a breakout. Volume is also increasing which is a sign that traders are taking note of this stock and are joining the race before the potential breakout.
The key level that GNPX needs to break over is $0.96-$1.00 and the next level/area after that to watch is $1.25-$1.30.
Clean Vision Corporation (OTC: CLNV) specializes in recognizing prominent enterprises and cutting-edge technologies that prioritize clean energy and sustainable solutions, catering to the present and future demands of global markets. The company endeavors to aid these emerging ventures in the green economy, enhancing the well-being of its customers, curbing greenhouse gas emissions, and delivering value to its shareholders. Among its expanding portfolio, Clean Vision Corp. currently comprises one enterprise named Clean-Seas, Inc., which excels in transforming waste plastics into eco-friendly fuels. Moreover, the consultancy services provided by Clean Vision Corp. bolster its portfolio companies by facilitating connections with new industries, expediting their time to market, and driving profitability.
On April 25, 2023, Clean Vision Corporation (OTCQB: CLNV) made an announcement regarding the successful completion of the acquisition of a 51% stake in Ecosynergie Group by its wholly owned subsidiary, Clean-Seas, Inc. Ecosynergie Group, a company based in Agadir, Morocco, specializes in sustainable products and solutions.
After the transaction's conclusion, Ecosynergie Group has been renamed Clean-Seas Morocco, LLC, operating under the new name. Starting in October 2023, Clean-Seas Morocco is expected to process 120 tons per day (TPD) of pyrolysis waste-plastic at its facility in Agadir.
Clean-Seas Morocco will act as a hub within the Plastic Conversion Network (PCN), focusing on the collection of waste plastic from North Africa and the European Union. The company aims to convert this waste plastic into a renewable and environmentally friendly source of green energy.
On May 18, 2023, Clean Vision Corporation made an announcement regarding its wholly owned subsidiary, Clean-Seas, Inc. The company will be acknowledged and honored by the Greater New York Chamber of Commerce at the highly regarded World Trade Week NYC 2023 event.
Mark Jaffe, the CEO of the Chamber, will recognize Dan Bates, the CEO of Clean-Seas, for his exceptional global leadership in promoting environmental sustainability. This recognition comes as the Greater New York Chamber gears up to launch its new Plastic Recycling & Sustainability Committee, which will be headed by Mr. Bates.
Since Wednesday, CLNV has experienced over a 20% move to the upside and is currently trying to breakout higher. The key area it needs to break for a potential continuation is that .038 area so keep it on watch for volume and confirmation. Also with all of the recent positive news on the company, that may just be enough to help breakout CLNV to the upside.
CNBX Pharmaceuticals Inc. (OTC: CNBX) is an advanced-stage biopharmaceutical company that specializes in the exploration, advancement, and commercialization of groundbreaking products and innovative technologies harnessing the potential of cannabinoids for treating cancer. By combining their exclusive technologies with the expertise of esteemed scientists, they strive to unlock the medicinal properties of cannabis and its diverse array of bioactive components. Through extensive testing on biopsies and cell lines, they have conducted numerous studies to understand how cannabinoids influence the cell cycle and cell death processes. At the heart of their operations lies a dynamic bioinformatics platform that continuously evolves, leveraging high throughput screening technology, advanced data analytics, artificial intelligence, and proprietary methodologies. This enables them to swiftly analyze the physiological effects of multiple cannabinoid compounds on tumor cells.
Their latest PR back on November 8, 2022, announced their acquisition of a controlling interest in TaGeza Biopharmaceuticals Ltd. Despite the acquisition, the dedicated research team at TaGeza remains fully committed to the company's mission. Prof. Benjamin Dekel (MD, PhD), co-founder of TaGeza, will continue to serve as the Chief Scientist, while Gabriel Yariv, Chairman of CNBX, will assume the role of CEO at TaGeza Biopharmaceuticals.
TaGeza, established in 2014 by a medical team from Sheba Medical Center, the largest hospital in Israel, focuses on developing advanced immunotherapy and cancer-targeted treatments. Currently, the company is working on pioneering Antibody Drug Conjugates (ADCs) based on novel monoclonal antibodies (mAbs) that specifically target Cancer Stem Cells (CSCs) or Tumor Initiating Cells (TICs), a highly tumorigenic subpopulation of cancer cells. By targeting CSCs/TICs, TaGeza aims to improve patient outcomes and reduce the risk of relapse, which often occurs due to the presence of chemotherapy-resistant tumor cells enriched by CSCs or TICs.
ADC therapies have gained significant traction in the global oncological therapeutics market. There are currently 11 Antibody Drug Conjugate therapies approved for marketing worldwide, with six of them receiving clearance in the past three years alone. ADCs are predominantly used in hematology and solid tumor therapy. Market analysis conducted by Nature in August 2021 indicates that several available ADCs generate annual sales exceeding $1 billion, and it is forecasted that the combined annual sales of currently marketed ADCs will exceed $16 billion by 2026.
CNBX's stock is currently experiencing some upwards movement with decent volume. A key level to watch for continuation breakout is 0.025. Also, this stock can be pretty volatile in either direction so make sure to manage your risk and keep an eye for any updates from the company.
Wolf Energy Services Inc. (OTC: WOEN), a corporation based in Florida, operates in the energy industry through its wholly owned subsidiary, Banner Midstream Corp., incorporated in Delaware. Banner offers two primary services: transportation of frac sand and logistics services to support hydraulic fracturing and drilling operations, known as "Transportation Services," and the provision of equipment procurement and financing services to contractors involved in oilfield transportation, referred to as "Procurement and Finance Services." These services are conducted through two wholly owned subsidiaries of Banner. Pinnacle Frac Transport LLC handles the Transportation Services, while Capstone Equipment Leasing LLC is responsible for the Procurement and Finance Services. Banner itself was established in 2018.
Frac sand hauling is a growing industry. As the popularity of natual gas and huydraulic fracturing (fracking) grow, drilling companies need an increasing amount of frac sand. Frac sand trucks and haulers provide the solution. Frac sand haulers are large commercial trailers capable of holding up to 1,000 cubic feet of sand weighing tens of thousands of pounds. Truck drivers connect their cabs to sand haulers and transport the sand to its destination.
In the past few months, WOEN's stock has experienced a pretty nicely sustained run. After a little dip last week, it just showed reversal signs with about 50% in gains in the past two days and looks to be potentially trying to breakout higher. Despite the low volume here, the tradable float is also pretty low sitting at 9.9m shares. Now the company hasn't submitted any PR's recently but make sure to keep an eye on this one in the near term.
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. We have been retained by a third party to assist in the production and distribution of content on Genprex Inc. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content.
CONTACT: CONTACT: Bigtimepennystocks.com
Editor: mail@bigtimepennystocks.com
.
GENPREX, INC. 
